General
Preferred name
NU6102
Synonyms
CDK1/2 inhibitor II, cmpd 3 ()
NU-6102 ()
NU 6102 ()
O6-CYCLOHEXYLMETHOXY-2-(4'-SULPHAMOYLANILINO) PURINE ()
P&D ID
PD006081
CAS
444722-95-6
Tags
available
drug candidate
Drug indication
Discovery agent
Drug Status
experimental
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION NU6102 is a potent CDK1 and CDK2 inhibitor with IC50s of 9.5 nM and 5.4 nM for CDK1/cyclinB and CDK2/cyclinA3, respectively. NU6102 shows selectivity for CDK1/CDK2 over CDK4 (IC50 of 1.6 ¦ÌM), DYRK1A (IC50 of 0.9 ¦ÌM), PDK1 (IC50 of 0.8 ¦ÌM) and ROCKII (IC50 of 0.6 ¦ÌM)[1][2].
PRICE 123
DESCRIPTION NU 6102 is a potent inhibitor of CDK1 and CDK2 with Ki values of 9 and 6 nM and IC50 values of 9.5 and 5.4 nM, respectively. NU 6102 inhibits Cdk4 activity with IC50 value of 1.6 μM. (BOC Sciences Bioactive Compounds)
DESCRIPTION NU6102 is a selective and potent ATP-competitive CDK2 inhibitor with antitumor activity against CDK1/cyclinB, CDK2/cyclinA3, CDK1/CDK2, CDK4, DYRK1A , PDK1, and ROCKII, and it can be used to study rectal cancer. (TargetMol Bioactive Compound Library)
Compound Sets
10
BOC Sciences Bioactive Compounds
nu-6102-cas-444722-95-6-291094
Cayman Chemical Bioactives
13317
CDK inhibitor database (CDKiDB)
CZ-OPENSCREEN Bioactive Library
DrugBank
DB07126
DrugMAP
DMMOFKD
EUbOPEN Chemogenomics Library
EUB0001625
LINCS compound set
10267-101
MedChem Express Bioactive Compound Library
HY-15569
TargetMol Bioactive Compound Library
T28218
External IDs
25
Properties
(calculated by RDKit )
Molecular Weight
402.15
Hydrogen Bond Acceptors
7
Hydrogen Bond Donors
3
Rotatable Bonds
6
Ring Count
4
Aromatic Ring Count
3
cLogP
2.7
TPSA
135.88
Fraction CSP3
0.39
Chiral centers
0.0
Largest ring
6.0
QED
0.58
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Target
CDK2
CDK
Pathway
Cell Cycle/Checkpoint
Cell Cycle/DNA Damage
Recommended Cell Concentration
None
Source data